SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation L24E

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 Influence of Corifollitropin Alfa (Elonva) on Embryo Morphokinetics and Fertility Treatment Outcome

The study evaluates the influence of corifollitropin alfa (Elonva) on embryo morphokinetics and fertility treatment outcome in comparison to a control group stimulated with Follitropin beta (Puregon).

NCT04142190 Infertility Drug: ELONVA Drug: PUREGON
MeSH:Infertility
HPO:Infertility

Follicular fluid (FF) were examined for oocytes under constant conditions of 37 °C in an IVF workstation L24E with heating stage (K-SYSTEMS Kivex Biotec A/S). --- L24E ---

Primary Outcomes

Description: Time of pronuclei disappearance in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Time of pronuclei disappearance

Time: 16-18 hours after fertilization

Description: The first observation of two discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Two discrete cells

Time: 26-28 hours after fertilization

Description: The first observation of three discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Three discrete cells

Time: 28-44 hours after fertilization

Description: The first observation of four discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Four discrete cells

Time: 44-45 hours after fertilization

Description: The first observation of five discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Five discrete cells

Time: 44-68 hours after fertilization

Description: The first observation of six discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Six discrete cells

Time: 44-68 hours after fertilization

Description: The first observation of seven discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Seven discrete cells

Time: 44-68 hours after fertilization

Description: The first observation of eight discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Eight discrete cells

Time: 68-69 hours after fertilization

Description: The first observation of nine discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Nine discrete cells

Time: 69-92 hours after fertilization

Description: End of the compaction process; when observable compaction is complete in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Morula stage

Time: 92 hours after fertilization

Secondary Outcomes

Description: The influence of ELONVA versus PUREGON on the number of oocytes retrieved will be assessed.

Measure: Number of oocytes retrieved

Time: Number of oocytes retrieved will be evaluated after one treatment cycle (each cycle is between 28 and 35 days)

Description: The influence of ELONVA versus PUREGON on the maturity stage of oocytes (germinal vesicle, metaphase I (MI) or MII phase) retrieved will be assessed.

Measure: Stage of oocyte development

Time: Stage of oocytes retrieved will be evaluated after one treatment cycle (each cycle is between 28 and 35 days)

Description: The influence of ELONVA versus PUREGON on the number of fertilized oocytes will be assessed.

Measure: Fertilized oocytes

Time: Number of fertilized oocytes will be evaluated after one treatment cycle (each cycle is between 28 and 35 days)

Description: The influence of ELONVA versus PUREGON on embryo grading (Istanbul consensus criteria) will be assessed. The grading consists of assessment of cell number, fragmentation, multinucleation, cell size, cytoplasmic granularity, membrane appearance, and the presence of vacuoles).

Measure: Embryo grading

Time: The quality of embryos will be evaluated after one treatment cycle (each cycle is between 28 and 35 days)

Description: The influence of Elonva versus Puregon on the number of biochemical pregnancies will be assessed.

Measure: Biochemical pregnancy (measurement of beta hCG)

Time: Biochemical pregnancies will be evaluated after successful implantation (1 week after embryo transfer)

Description: The influence of Elonva versus Puregon on the number of life births will be assessed.

Measure: Life birth

Time: Life births will be evaluated after successful pregnancy (9 moths after embryo transfer)

Description: The influence of Elonva versus Puregon on the weight of the newborn will be assessed.

Measure: Weight (kilograms)

Time: Weight of the newborn will be evaluated after birth (9 moths after embryo transfer)

Description: The influence of Elonva versus Puregon on the height of the newborn will be assessed.

Measure: Height (centimeters)

Time: Height of the newborn will be evaluated after birth (9 moths after embryo transfer)


HPO Nodes